Company Profile

n/a (: n/a)
Pricing data not available
Detailed Quote
Open: $ n/a   Volume: n/a
High: $ n/a   Yield(%) n/a
Low: $ n/a   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): n/a
EPS ($) n/a   Shares Out: n/a
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): 0.00
% Price Change (last 13 weeks): -87.50
% Price Change (last 26 weeks): -98.58
% Price Change (last 52 weeks): -99.18
% Price Change (year to date): -100.00
Management Effectiveness
Return on Equity (%): n/a
Return on Assets (%): -283.33
Return on Invested Capital (%): n/a
Profitability
Gross Profit Margin (%): n/a
Net Profit Margin (%): n/a
Operating Profit Margin (%): 0.00
Price & Volume
50-day Moving Average: $n/a
200-day Moving Average: $n/a
Avg. Daily Vol. (last 50 days): n/a
Avg. Daily Vol. (last 200 days): n/a
52-wk high: $n/a
52-wk low: $n/a
Bid: $n/a
Ask: $n/a
Company Information
Rebus Holdings, Inc. is a pharmaceutical company engaged in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.
n/a
2629 Townsgate Road Suite 215
Westlake Village CA 91361

Phone: 1.818.597.7552
Fax: n/a
http://www.inspyrtherapeutics.com
Per Share Data
Earnings (1year) ($): 0.01
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): -0.16
Cash Flow ($): -0.03
Valuation Ratios
Price/Earnings (x): 0.01
Price/Sales (x): n/a
Price/Book (x): n/a
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): 0.00
Current Ratio (x): 0.00
LT Debt/Equity (x): n/a
Total Debt/Equity (x): n/a



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.